Seeking Alpha
All posts from Seeking Alpha
Seeking Alpha in Seeking Alpha - Read, Decide, Invest.,

Post-Earnings, Alexion Is Financed Heading Into Q1 Regulatory Catalysts

Alexion Pharmaceuticals (NASDAQ:ALXN) is a large global biopharmaceutical company focused on therapies for severe and life-threatening rare diseases. The company's sole commercial product is Soliris (eculizumab), the world's first and only approved terminal complement inhibitor. Based largely on the success of Soliris since the 2007 approval, Alexion's market cap has swelled to $36.33 billion. On January 26, Alexion announced financial results for the quarter and year-ended December 31, 2014, highlighted by a 44% increase in Soliris net product…